Xeris Announces Changes to Its Board of Directors
Xeris Biopharma Holdings (Nasdaq: XERS) announced changes to its Board of Directors. Ricki Fairley has resigned effective immediately, while John Schmid will not seek re-election at the 2025 Annual Stockholders Meeting, which will reduce the board size to eight members.
The company has appointed James Brady as a new director to fill the immediate vacancy. Brady brings over thirty years of experience from AstraZeneca, where he held various leadership positions, most recently serving as Chief Financial Officer of MedImmune, AstraZeneca's biologics discovery and development division. He currently serves on the Board of Directors and Audit Committee of Verona Pharma plc (Nasdaq: VRNA).
Xeris Biopharma Holdings (Nasdaq: XERS) ha annunciato cambiamenti nel suo Consiglio di Amministrazione. Ricki Fairley si è dimessa con effetto immediato, mentre John Schmid non si presenterà per la rielezione alla Riunione Annuale degli Azionisti del 2025, il che ridurrà la dimensione del consiglio a otto membri.
L'azienda ha nominato James Brady come nuovo direttore per coprire la posizione vacante immediata. Brady porta con sé oltre trent'anni di esperienza in AstraZeneca, dove ha ricoperto varie posizioni di leadership, servendo più recentemente come Chief Financial Officer di MedImmune, la divisione di scoperta e sviluppo biologico di AstraZeneca. Attualmente è membro del Consiglio di Amministrazione e del Comitato di Revisione di Verona Pharma plc (Nasdaq: VRNA).
Xeris Biopharma Holdings (Nasdaq: XERS) anunció cambios en su Junta Directiva. Ricki Fairley ha renunciado con efecto inmediato, mientras que John Schmid no buscará la reelección en la Reunión Anual de Accionistas de 2025, lo que reducirá el tamaño de la junta a ocho miembros.
La compañía ha nombrado a James Brady como nuevo director para ocupar la vacante inmediata. Brady aporta más de treinta años de experiencia de AstraZeneca, donde ocupó varios puestos de liderazgo, sirviendo más recientemente como Director Financiero de MedImmune, la división de descubrimiento y desarrollo biológico de AstraZeneca. Actualmente es miembro de la Junta Directiva y del Comité de Auditoría de Verona Pharma plc (Nasdaq: VRNA).
Xeris Biopharma Holdings (Nasdaq: XERS)는 이사회에 변화를 발표했습니다. Ricki Fairley는 즉시 사임하였고, John Schmid는 2025년 연례 주주 총회에서 재선에 나서지 않을 것입니다. 이로 인해 이사회 규모는 여덟 명으로 줄어듭니다.
회사는 즉각적인 공석을 채우기 위해 James Brady를 새로운 이사로 임명했습니다. Brady는 AstraZeneca에서 30년 이상의 경험을 쌓았으며, 최근에는 AstraZeneca의 생물학적 발견 및 개발 부서인 MedImmune의 최고 재무 책임자로 재직했습니다. 그는 현재 Verona Pharma plc (Nasdaq: VRNA)의 이사회 및 감사 위원회에서 활동하고 있습니다.
Xeris Biopharma Holdings (Nasdaq: XERS) a annoncé des changements au sein de son Conseil d'Administration. Ricki Fairley a démissionné avec effet immédiat, tandis que John Schmid ne se représentera pas à l'Assemblée Générale Annuelle des Actionnaires de 2025, ce qui réduira la taille du conseil à huit membres.
L'entreprise a nommé James Brady comme nouveau directeur pour combler le poste vacant immédiat. Brady apporte plus de trente ans d'expérience d'AstraZeneca, où il a occupé divers postes de direction, ayant récemment été directeur financier de MedImmune, la division de découverte et de développement biologique d'AstraZeneca. Il siège actuellement au Conseil d'Administration et au Comité d'Audit de Verona Pharma plc (Nasdaq: VRNA).
Xeris Biopharma Holdings (Nasdaq: XERS) hat Änderungen in seinem Vorstand bekannt gegeben. Ricki Fairley hat mit sofortiger Wirkung zurückgetreten, während John Schmid sich nicht zur Wiederwahl bei der Jahreshauptversammlung 2025 stellen wird, was die Größe des Vorstands auf acht Mitglieder reduzieren wird.
Das Unternehmen hat James Brady als neuen Direktor ernannt, um die sofortige Vakanz zu füllen. Brady bringt über dreißig Jahre Erfahrung von AstraZeneca mit, wo er verschiedene Führungspositionen innehatte und zuletzt als Finanzvorstand von MedImmune, der Abteilung für biologische Entdeckung und Entwicklung von AstraZeneca, tätig war. Derzeit ist er Mitglied des Vorstands und des Prüfungsausschusses von Verona Pharma plc (Nasdaq: VRNA).
- Appointment of experienced financial executive James Brady with over 30 years of biopharmaceutical industry expertise
- Brady's current board experience at Verona Pharma (VRNA) adds public company oversight capability
- Loss of two board members, including immediate resignation of Ricki Fairley
- Reduction in board size to eight members by 2025
“I am honored to welcome Jim to our Board of Directors at this pivotal time in Xeris’ growth journey. Jim is a seasoned and savvy business professional deeply steeped in the biopharmaceutical industry with broad-ranging public company financial expertise. He will add to the depth and breadth of our board and will be invaluable as we continue to drive innovation and expand our market presence,” said Marla Persky, Chairperson of the Board of Directors. “On behalf of the entire Board, I’d like to thank John Schmid for his years of dedication to Xeris and excellent contributions to the Board. We also thank Ricki Fairley for her marketing and patient community insights.”
Mr. Brady is an experienced international business executive who served in multiple leadership roles of increasing responsibility for AstraZeneca prior to his retirement. His more than thirty years of progressive experience at AstraZeneca included successful national, regional, and global finance roles in corporate operations, manufacturing, commercial, marketing, market access, audit, international business, and biologics discovery and development. Mr. Brady most recently served as Chief Financial Officer of MedImmune, the biologics discovery and development division of AstraZeneca. He currently serves on the Board of Directors and as a Member of the Audit Committee of Verona Pharma plc (Nasdaq: VRNA). Mr. Brady received his BS in Accounting from
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
Forward-Looking Statements
Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K filed with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250328700717/en/
Xeris Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
Who is joining Xeris Biopharma's (XERS) Board of Directors in 2024?
How many members will be on Xeris' (XERS) Board after the 2025 Annual Stockholders Meeting?
What experience does James Brady bring to Xeris' (XERS) Board?
Which board members are leaving Xeris Biopharma (XERS)?
